Halozyme to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Halozyme Therapeutics (NASDAQ: HALO) has announced its upcoming participation in two major investor conferences. The company's CEO, Dr. Helen Torley, will attend the Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, for one-on-one meetings. Additionally, she will participate in a fireside chat and investor meetings at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 7:00 AM PT / 10:00 AM ET.
The presentation at the Goldman Sachs conference will be available via live audio webcast in the Investor Relations section of Halozyme's website, with replays accessible for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – HALO
On the day this news was published, HALO gained 0.55%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Details on the Company's participation are as follows:
Event: | Benchmark 2025 Healthcare House Call Virtual Conference | |||
Format: | 1x1 Meetings | |||
Date: | Thursday, May 29, 2025 | |||
Event: | Goldman Sachs 46th Annual Global Healthcare Conference 2025 | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Date: | Monday, June 9, 2025 | |||
Presentation Time: | 7:00am PT / 10:00am ET |
A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302467398.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the Goldman Sachs Healthcare Conference 2025?
Who will represent Halozyme (HALO) at the upcoming investor conferences?
Which investor conferences will Halozyme (HALO) attend in May-June 2025?
How can investors access Halozyme's (HALO) presentation at the Goldman Sachs conference?
